Monte Rosa Therapeutics (GLUE) Accumulated Depreciation & Amortization: 2023-2025
Historic Accumulated Depreciation & Amortization for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $25.5 million.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization rose 39.44% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.6 million, marking a year-over-year increase of 48.83%. This contributed to the annual value of $20.4 million for FY2024, which is 66.32% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization is $25.5 million, which was up 8.94% from $23.4 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $25.5 million during Q3 2025, with a 5-year trough of $8.6 million in Q2 2023.
- Its 3-year average for Accumulated Depreciation & Amortization is $16.6 million, with a median of $16.2 million in 2024.
- Data for Monte Rosa Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 89.16% (in 2024) over the last 5 years.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $12.2 million in 2023, then spiked by 66.32% to $20.4 million in 2024, then soared by 39.44% to $25.5 million in 2025.
- Its last three reported values are $25.5 million in Q3 2025, $23.4 million for Q2 2025, and $21.3 million during Q1 2025.